Skip to main content
Bioceltix S.A. logo

Bioceltix S.A. — Investor Relations & Filings

Ticker · BCX ISIN · PLBCLTX00019 LEI · 259400QZD5JYK8SLZU51 WAR Manufacturing
Open in API
Filings indexed 270 across all filing types
Latest filing 2023-09-26 Regulatory Filings
Country PL Poland
Listing WAR BCX

About Bioceltix S.A.

https://bioceltix.com/en/

Bioceltix S.A. is a biopharmaceutical company that develops stem cell-based medicinal products for veterinary use. The company focuses on creating therapies that utilize Mesenchymal Stem Cells (MSCs) as the active pharmaceutical ingredient. Its product pipeline is aimed at treating immunological and inflammatory conditions in companion animals, including dogs, cats, and horses. A key area of development includes treatments for conditions such as atopic dermatitis in dogs and degenerative joint disease.

Recent filings

Filing Released Lang Actions
Wyniki końcowe weterynaryjnego badania klinicznego dotyczącego potwierdzenia skuteczności i bezpieczeństwa produktu BCX-CM-J - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement by the Management Board ('Zarząd') of Bioceltix S.A. regarding the successful final results of a veterinary clinical trial for a product (BCX-CM-J) treating osteoarthritis in dogs. It details statistical outcomes, patient groups, endpoints, and the decision to proceed with regulatory submission to the European Medicines Agency. This content relates to the company's operational progress, specifically concerning product development and regulatory steps, but it is not a full financial report (10-K, IR), a general earnings release (ER), or a management discussion/analysis (MDA). Since it is a specific update on a significant operational/development milestone that doesn't fit the other specific categories (like M&A, Capital, or Director's Dealing), it falls best under the general 'Regulatory Filings' (RNS) category as a significant, non-financial regulatory-adjacent announcement, or potentially a Legal/Regulatory update (LTR) if the trial results were mandated by a regulator, but RNS is the most appropriate catch-all for material operational news not covered elsewhere. Given the context of Polish regulatory filings (ESPI reports mentioned), RNS (Regulatory Filings) is the standard classification for material, non-periodic, non-financial announcements.
2023-09-26 Polish
Zgoda Rady Nadzorczej na sprzedaż przez członków Zarządu akcji stanowiących 2,6% w kapitale zakładowym Spółki - Content (PL)
Director's Dealing Classification · 1% confidence The document discusses the sale of shares by company directors (Łukasz Bzdzion and Paweł Wielgus) and the associated extension of lock-up agreements, requiring approval from the Supervisory Board. This directly relates to personal share transactions by company directors and executives, which falls under the definition of Director's Dealing (DIRS). Although it involves capital structure changes (share sales), the core subject is the insider transaction disclosure and associated agreements.
2023-09-22 Polish
Korekta raportu bieżącego Spółki nr 52/2023 z dnia 21 września 2023 r. - Content (PL)
Board/Management Information Classification · 1% confidence The document is a correction ('korekta') to a previous current report ('raport bieżący') issued by the management board ('Zarząd') of Bioceltix S.A. It concerns the approval by the Supervisory Board for management members to sell shares, specifically correcting a date related to a lock-up agreement for the CEO. This type of announcement, detailing insider transactions (share sales by management) and related corporate governance/insider restrictions (lock-up agreements), most closely aligns with insider trading reports or general corporate governance disclosures. Since the core subject is the transaction/dealing by directors/executives, the most appropriate category is Director's Dealing (DIRS). It is not a standard financial report (10-K, IR, ER) nor a general regulatory filing (RNS), as it addresses a specific insider action.
2023-09-22 Polish
Deklaracja woli zawarcia przez Kvarko Group ASI sp. z o.o. umowy lock-up w odniesieniu do akcji Spółki - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is in Polish and discusses a declaration of intent ('deklarację woli') by a shareholder (Kvarko Group) to enter into a lock-up agreement ('umowy ograniczającej zbywanie akcji') concerning the sale of shares by company executives (Paweł Wielgus and Andrij Włach) in connection with planned public offerings described in a previous report (Raport ws. ABB). This action relates to restrictions on share disposal by insiders/major shareholders following potential transactions or capital events. This fits best under Major Shareholding Notification (MRQ) as it concerns significant shareholder actions and restrictions on share disposal, or potentially Regulatory Filings (RNS) if it's a specific mandatory disclosure not covered elsewhere. Given the focus on a shareholder agreement restricting the disposal of shares, MRQ is the most specific fit among the provided options, as it deals with changes/restrictions related to significant ownership.
2023-09-21 Polish
Zawiadomienie akcjonariuszy o zamiarze sprzedaży akcji Spółki w ramach ofert publicznych w trybie przyspieszonego budowania księgi popytu. Zwolnienie akcjonariuszy ze zobowiązań lock-up na potrzeby...
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from Bioceltix S.A. (Emitent) detailing notifications received from major shareholders regarding their intention to conduct a public offering (sale) of a significant number of shares (up to 365,876 shares) via an accelerated book-building process ('ABB'). It also discusses the waiver of lock-up agreements for some of these shareholders. This type of announcement, concerning the intent of major shareholders to sell a large block of shares, often involving capital structure changes or significant ownership shifts, aligns best with 'Capital/Financing Update' (CAP) or potentially 'Major Shareholding Notification' (MRQ) if it were only about the change in holding percentage. However, since it explicitly details a planned public offering/sale by existing large shareholders, it falls under activities related to capital structure changes or significant transactions. Given the options, 'CAP' (Capital/Financing Update) is the most appropriate fit as it describes a major transaction affecting the share capital structure, even if initiated by shareholders. It is not a standard 10-K, ER, or IR. It is a specific corporate action announcement.
2023-09-19 Polish
Raport półroczny Bioceltix S.A. za I półrocze 2023 r. zawierający odpowiednią informację dodatkową
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPORT PÓŁROCZNY' (Semi-annual Report) for Bioceltix S.A. covering the first half of 2023. It contains a management letter, a table of contents, selected financial data, and a condensed financial statement. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data and analysis for a period shorter than a full fiscal year. H1 2023
2023-09-18 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.